Our Research

FAST Australia is committed to advancing Australian research while maintaining a strong collaborative relationship with FAST United States and global patient organizations. We focus our efforts on determining areas of unmet Angelman syndrome research in line with the global vision for a cure and identify opportunities to fund research to address those gaps. Read more about how/where we have invested funds in research below.

Enabling

Tools & resources that will allow research into our ultimate goal to progress.

Global Angelman Syndrome Registry
- Registry Curator/ Research Assistant (Mater Research Institute)
- TranSMART analytical platform (Clarivate Analytics)
Generation of an Angelman syndrome model cell line (University of Sydney)
Generation of mouse lines expressing human UBE3A antisense (co-funded with FAST United States)
Development and characterisation of a pig model of AS (co-funded with FAST United States)
Quantifying EEG Abnormalities and identifying biomarkers in Angelman syndrome (Co-funded with the Angelman Syndrome Alliance)

Learning

Basic science that will help us understand more about the syndrome to propel research.

RNA binding motifs as therapeutic targets for Angelman syndrome (University of Sydney)
Expression profiling for mechanisms of minocycline action (Queensland Bioinformatics)
Health Economics in Angelman syndrome
Incidence of Food Sensitivity and Gut Dysbiosis in Angelman syndrome
(Co-funded with FAST United States and FAST United Kingdom)

Treatments

Discovering therapeutics that alleviate one or more symptoms of Angelman syndrome

Potential therapeutic approach for synaptic deficit in Angelman syndrome
(Co-funded with the Angelman Syndrome Alliance)

Our Research

Enabling

Learning

Treatments

Blog

Neuren Australian Clinical Trial

Centre of Excellence

Positive Interim Phase 1/2 Data

Quick Links

Keep in Touch